Teva s ProAir R HFA the Market
Selected Abstract
Teva's ProAir(R) HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication.
JERUSALEM -- Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir([R]) HFA (albuterol sulfate) Inhalation Aerosol for use in patients as young as 4 years of age. Previously, ProAir HFA had been indicated for use in patients aged 12 ... September 23, 2008; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Teva's ProAir(R) HFA, the Market Leading Albuterol Inhaler, Receives New Pediatric Indication.
|
